If we take the Clendon’s funding facilities is an indication, it is for the purpose to fund each drug to end of phase 2. The funding facility will be for a period of 2 years with the clock starting from the first drawdown on each drug.
For IRX211, the clock is ticking now, so we should expect the end of phase 2 should be within the next 22 months or so.
I believe the team had paid lots of attention to the design of the trials for the purpose of meeting the FDA requirements, and the designs are important for the success of the trials. Having done that and now with HREC approval of the design, it is going to be an interesting 22 months ahead.
Add to My Watchlist
What is My Watchlist?
